Your browser doesn't support javascript.
IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes.
Garrido, Jose L; Medina, Matías A; Bravo, Felipe; McGee, Sarah; Fuentes-Villalobos, Francisco; Calvo, Mario; Pinos, Yazmin; Bowman, James W; Bahl, Christopher D; Barria, Maria Ines; Brachman, Rebecca A; Alvarez, Raymond A.
  • Garrido JL; Ichor Biologics LLC, New York, NY 10027, USA; Facultad de Medicina y Ciencia, Universidad San Sebastián, Puerto Montt 5480000, Chile.
  • Medina MA; Department of Microbiology, Faculty of Biological Science, Universidad de Concepción, Concepción 4070386, Chile.
  • Bravo F; Ichor Biologics LLC, New York, NY 10027, USA; Department of Microbiology, Faculty of Biological Science, Universidad de Concepción, Concepción 4070386, Chile.
  • McGee S; Ichor Biologics LLC, New York, NY 10027, USA.
  • Fuentes-Villalobos F; Department of Microbiology, Faculty of Biological Science, Universidad de Concepción, Concepción 4070386, Chile.
  • Calvo M; Institute of Medicine, Universidad Austral de Chile, Valdivia 5110566, Chile.
  • Pinos Y; Hospital Base San José, Osorno 5290000, Chile.
  • Bowman JW; Institute for Protein Innovation, Harvard Institutes of Medicine, Boston, MA 02115, USA; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA; AI Proteins, Andover, MA 01810, USA.
  • Bahl CD; Institute for Protein Innovation, Harvard Institutes of Medicine, Boston, MA 02115, USA; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA; AI Proteins, Andover, MA 01810, USA.
  • Barria MI; Facultad de Medicina y Ciencia, Universidad San Sebastián, Puerto Montt 5480000, Chile.
  • Brachman RA; Jacobs Technion-Cornell Institute, Cornell Tech, Cornell University, New York, NY 10044, USA; 525 Bio LLC, New York, NY 10044, USA.
  • Alvarez RA; Ichor Biologics LLC, New York, NY 10027, USA; 525 Bio LLC, New York, NY 10044, USA; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: ralvarez@ichorbiologics.com.
Cell Rep ; 39(9): 110904, 2022 05 31.
Article in English | MEDLINE | ID: covidwho-1926270
ABSTRACT
Despite SARS-CoV-2 being a "novel" virus, early detection of anti-spike IgG in severe COVID-19 patients may be caused by the amplification of humoral memory responses against seasonal coronaviruses. Here, we examine this phenomenon by characterizing anti-spike IgG responses in non-hospitalized convalescent individuals across a spectrum of COVID-19 severity. We observe that disease severity positively correlates with anti-spike IgG levels, IgG cross-reactivity against other betacoronaviruses (ß-CoVs), and FcγR activation. Analysis of IgG targeting ß-CoV-conserved and non-conserved immunodominant epitopes within the SARS-CoV-2 spike protein revealed epitope-specific relationships IgG targeting the conserved heptad repeat (HR) 2 region significantly correlates with milder disease, while targeting the conserved S2'FP region correlates with more severe disease. Furthermore, a lower HR2-to-S2'FP IgG-binding ratio correlates with greater disease severity, with ICU-hospitalized COVID-19 patients showing the lowest HR2/S2'FP ratios. These findings suggest that HR2/S2'FP IgG profiles may predict disease severity and offer insight into protective versus deleterious humoral recall responses.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Cell Rep Year: 2022 Document Type: Article Affiliation country: J.celrep.2022.110904

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Cell Rep Year: 2022 Document Type: Article Affiliation country: J.celrep.2022.110904